These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12402208)

  • 21. Priming for immunologic memory in adults by meningococcal group C conjugate vaccination.
    Vu DM; de Boer AW; Danzig L; Santos G; Canty B; Flores BM; Granoff DM
    Clin Vaccine Immunol; 2006 Jun; 13(6):605-10. PubMed ID: 16760316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom.
    Borrow R; Goldblatt D; Finn A; Southern J; Ashton L; Andrews N; Lal G; Riley C; Rahim R; Cartwright K; Allan G; Miller E
    Infect Immun; 2003 Oct; 71(10):5549-55. PubMed ID: 14500473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and immunological priming of the serogroup a portion of a bivalent meningococcal A/C conjugate vaccine in 2-year-old children.
    Joseph H; Ryall R; Bybel M; Papa T; MacLennan J; Buttery J; Borrow R
    J Infect Dis; 2003 Apr; 187(7):1142-6. PubMed ID: 12660929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine.
    Vu DM; Welsch JA; Zuno-Mitchell P; Dela Cruz JV; Granoff DM
    J Infect Dis; 2006 Mar; 193(6):821-8. PubMed ID: 16479517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial.
    Lieberman JM; Chiu SS; Wong VK; Partidge S; Chang SJ; Chiu CY; Gheesling LL; Carlone GM; Ward JI
    JAMA; 1996 May; 275(19):1499-503. PubMed ID: 8622225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study.
    Stoof SP; Heijstek MW; Sijssens KM; van der Klis F; Sanders EA; Teunis PF; Wulffraat NM; Berbers GA
    Ann Rheum Dis; 2014 Apr; 73(4):728-34. PubMed ID: 23505231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age.
    Tejedor JC; Moro M; Merino JM; Gómez-Campderá JA; García-del-Rio M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Ruiz-Contreras J; Martin-Ancel A; Roca J; Boceta R; García-Corbeira P; Maechler G; Boutriau D;
    Pediatr Infect Dis J; 2008 Jul; 27(7):579-88. PubMed ID: 18536619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years.
    McVernon J; MacLennan J; Pollard AJ; Oster P; Wakefield MJ; Danzig L; Moxon ER
    Pediatr Infect Dis J; 2003 Jul; 22(7):659-61. PubMed ID: 12886896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.
    Tejedor JC; Merino JM; Moro M; Navarro ML; Espín J; Omeñaca F; García-Sicilia J; Moreno-Pérez D; Ruiz-Contreras J; Centeno F; Barrio F; Cabanillas L; Muro M; Esporrin C; De Torres MJ; Caubet M; Boutriau D; Miller JM; Mesaros N
    Pediatr Infect Dis J; 2012 Oct; 31(10):1074-7. PubMed ID: 22828645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals.
    Balmer P; Falconer M; McDonald P; Andrews N; Fuller E; Riley C; Kaczmarski E; Borrow R
    Infect Immun; 2004 Jan; 72(1):332-7. PubMed ID: 14688112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults: An Open, Randomized Trial.
    Baxter R; Baine Y; Kolhe D; Baccarini CI; Miller JM; Van der Wielen M
    Pediatr Infect Dis J; 2015 Nov; 34(11):1236-43. PubMed ID: 26237742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum antibody kinetics following nasal or parenteral challenge with meningococcal polysaccharide in healthy adults.
    Findlow H; Borrow R; Hardelid P; Newton E; Frankland S; Naylor S; Miller E; Kaczmarski E; Read RC
    Clin Vaccine Immunol; 2011 Mar; 18(3):424-9. PubMed ID: 21248159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.
    MacLennan J; Obaro S; Deeks J; Lake D; Elie C; Carlone G; Moxon ER; Greenwood B
    J Infect Dis; 2001 Jan; 183(1):97-104. PubMed ID: 11087205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B cell memory to a serogroup C meningococcal conjugate vaccine in childhood and response to booster: little association with serum IgG antibody.
    Perrett KP; Jin C; Clutterbuck E; John TM; Winter AP; Kibwana E; Yu LM; Curtis N; Pollard AJ
    J Immunol; 2012 Sep; 189(5):2673-81. PubMed ID: 22855707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
    Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
    Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
    Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
    Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meningococcal serogroup C polysaccharide specific memory B cells, directly enumerated by labeled polysaccharide, are not affected by age at vaccination.
    Henneken M; Burdin N; Thoroddsen E; Sigurdardottir ST; Trannoy E; Jonsdottir I
    Vaccine; 2010 Feb; 28(9):2097-103. PubMed ID: 20056181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural and vaccine-induced immunity to Neisseria meningitidis serogroup C in asplenic patients with β-thalassemia.
    Spoulou V; Tzanakaki G; Lekka S; Chouliaras G; Ladis V; Theodoridou M
    Vaccine; 2011 Jun; 29(27):4435-8. PubMed ID: 21497638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response.
    Blanchard Rohner G; Snape MD; Kelly DF; John T; Morant A; Yu LM; Borkowski A; Ceddia F; Borrow R; Siegrist CA; Pollard AJ
    J Immunol; 2008 Feb; 180(4):2165-73. PubMed ID: 18250423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.
    de Whalley PC; Snape MD; Plested E; Thompson B; Nuthall E; Omar O; Borrow R; Pollard AJ
    Arch Dis Child; 2013 Sep; 98(9):686-91. PubMed ID: 23853000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.